These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24418117)

  • 21. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
    Kanazu M; Maruyama K; Ando M; Asami K; Ishii M; Uehira K; Minomo S; Matsuda Y; Kawaguchi T; Atagi S; Ogawa Y; Kusunoki Y; Takada M; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):182-7. PubMed ID: 24518101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment.
    Baxa J; Matouskova T; Krakorova G; Schmidt B; Flohr T; Sedlmair M; Bejcek J; Ferda J
    Eur Radiol; 2016 Aug; 26(8):2828-36. PubMed ID: 26563350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

  • 26. Lung cancer: positron emission tomography/computed tomography and the new staging system.
    Rakheja R; Ko JP; Friedman K
    Semin Roentgenol; 2013 Oct; 48(4):308-22. PubMed ID: 24034263
    [No Abstract]   [Full Text] [Related]  

  • 27. Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients.
    Li S; Zhao B; Wang X; Yu J; Yan S; Lv C; Yang Y
    Clin Radiol; 2014 Aug; 69(8):e352-7. PubMed ID: 24877581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography with 2-[18f]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy?
    Kernstine KH
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1700-3. PubMed ID: 14688674
    [No Abstract]   [Full Text] [Related]  

  • 29. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcoid-like reaction mimics progression of disease after induction chemotherapy for lung cancer.
    Chida M; Inoue T; Honma K; Murakami K
    Ann Thorac Surg; 2010 Dec; 90(6):2031-3. PubMed ID: 21095358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.
    Novello S
    J Clin Oncol; 2015 Dec; 33(34):3985-6. PubMed ID: 26438112
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
    Hirsch FR; Bunn PA
    Nat Rev Clin Oncol; 2015 Dec; 12(12):689-90. PubMed ID: 26552954
    [No Abstract]   [Full Text] [Related]  

  • 34. Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
    Goepel L; Jacobi A; Augustin M; Radtke MA
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e311-e313. PubMed ID: 29430731
    [No Abstract]   [Full Text] [Related]  

  • 35. Invited commentary.
    Force S
    Ann Thorac Surg; 2014 Aug; 98(2):422-3. PubMed ID: 25087783
    [No Abstract]   [Full Text] [Related]  

  • 36. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    Reck M; Rabe KF
    N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
    [No Abstract]   [Full Text] [Related]  

  • 37. Osteoblastic healing response: discordant PET/CT findings.
    Gemmel F; Eshuis SA; van Vollenhoven F; Gemmel P
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):184-5. PubMed ID: 21997719
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug companies settle claim of misleading doctors on cancer survival data.
    Dyer O
    BMJ; 2016 Jun; 353():i3361. PubMed ID: 27307418
    [No Abstract]   [Full Text] [Related]  

  • 39. How should we manage non-small-cell lung cancer "not-otherwise-specified"?
    Kim YH; Nishimura Y; Funada Y
    Med Oncol; 2021 Jun; 38(7):82. PubMed ID: 34117925
    [No Abstract]   [Full Text] [Related]  

  • 40. Ipilimumab in cancer patients: the issue of early metabolic response.
    Chargari C; Le Moulec S; Bonardel G; Foehrenbach H; Védrine L
    Anticancer Drugs; 2013 Mar; 24(3):324-6. PubMed ID: 23348246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.